00:00There is no doubt that the advent of biological therapies for monoclonal antibodies has revolutionized
00:12the management of serious asthma.
00:14The goal declared from the beginning was to reduce the use of steroids for systemic reasons
00:22until complete suspension, and we can say that biological therapies have allowed us to achieve this goal,
00:31as well as the reduction of the frequency of re-acutization and the control of symptoms.
00:39Today we are quite confident that with biological therapies we can achieve clinical remission in a good number of patients.
00:50The real challenge is to maintain clinical remission over the years, and the initial data tell us that this is possible
00:57at least in the three years of observation, but we can also aim at biological remission,
01:03which, by extinguishing inflammation, can have an impact on the natural history of the disease,
01:09on the progression of the disease, therefore essentially modifying the disease itself.
01:15The clinical trials with the use of mepolizumab in patients with serious asthma
01:24have confirmed the effectiveness of the drug in the clear reduction,
01:30since the first supply of re-acutization, on the control of symptoms and on the improvement.
01:37The confirmation was made by the studies of Real Life.
01:41The Reality AI is certainly the study that has confirmed, in the two years of observation,
01:48not only the improvement since the initial phases, but also the maintenance of this gain in terms of quality of life
01:57and the clinical and biological parameters that have been analyzed.
02:01The future is to evaluate in a longer period of time the maintenance of clinical remission.
02:10The data are encouraging in this sense, but also the clinical experience that anyone who works on the field
02:19knows that it can hold and know that it can count on an effective drug like antithelioquine 5 and mepolizumab.
Comments